other material
confidence high
sentiment positive
materiality 0.60
Quoin achieves 4% and 5% rapamycin loadings in topical and patch; clinical testing planned H1 2026
Quoin Pharmaceuticals, Ltd.
- Rapamycin loading 4% w/w in proprietary topical formulation; 5% w/w in dermal patch system.
- Clinical trial and stability batch manufacture to start Q4 2025; clinical testing in H1 2026.
- Initial targets: Microcystic Lymphatic Malformations and Venous Malformations (no FDA-approved treatments).
- CEO notes capital raise completed to fund Netherton Syndrome pivotal studies and advance rapamycin programs.
- Milestone complements ongoing late-stage Netherton Syndrome and Peeling Skin Syndrome development.